Diagnosing venous thromboembolism (VTE) can be challenging, especially in patients admitted for another medical condition such as cancer, kidney failure or even pregnancy.
A great number of patients every year experience thrombosis. Thankfully, once detected, VTE is treatable.
LEO Pharma has been developing heparin-based products to combat VTE since the 1940s. Harnessing all our knowledge and experience, we are committed to helping healthcare professionals identify and treat high-risk patient groups for VTE – and to prevent needless
suffering and loss of life.
The challenge for healthcare professionals lies in the characteristics of the patients that are commonly diagnosed with VTE- especially cancer patients. Many of them have co-morbidities, use concomitant medications and, as a result, may present with a burdened physiological profile.
Despite these challenges, heparin-based products continue to be an essential part of thrombosis prophylaxis as well as treatment.
At LEO Pharma, we have more than 70 years of experience helping healthcare professionals meet their daily clinical challenges in managing thrombosis.
Which site would you like to visit?